News & Articles

Singapore Venture Creation Group 65LAB Awards US$1.69 million to A*STAR-led Project Targeting the Cause of Vision Loss in Glaucoma and NAION

First 65LAB award to a project led by Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, extending support for

Singapore venture creation group 65LAB funds NUS novel biologics project targeting lung diseases

65LAB, a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund alongside Evotec, has funded

65LAB awards US$1.5 million to Duke-NUS platform to advance antifibrotic drug discovery

Recipient Professor Enrico Petretto from Duke-NUS is spearheading groundbreaking research to develop new drugs for lung disease and uncover new therapeutic targets for kidney

65LAB and Duke-NUS award US$1.85 million to combat chronic inflammation

Recipient Associate Professor Lena Ho spearheads groundbreaking research to develop first-in-class therapeutics to target inflammatory diseases Collaboration between 65LAB and Duke-NUS aims to advance